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Objective: To compare the effectiveness of bucindolol and metoprolol succinate for the 
maintenance of sinus rhythm in a genetically defined heart failure (HF) population with atrial 
fibrillation (AF).  
Background: Bucindolol is a beta-blocker whose unique pharmacologic properties provide 
greater benefit in HF patients with reduced ejection fraction (HFrEF) who have the beta1-
adrenergic receptor (ADRB1) Arg389Arg genotype. 
Methods: 267 HFrEF patients with a left ventricular ejection fraction (LVEF) < 0.50, 
symptomatic AF, and the ADRB1 Arg389Arg genotype were randomized 1:1 to bucindolol or 
metoprolol and up-titrated to target doses. The primary endpoint of AF/atrial flutter (AFL) or all-
cause mortality (ACM) was evaluated by electrocardiogram (ECG) during a 24-week period.  
Results: The hazard ratio (HR) for the primary endpoint was 1.01 (95% CI: 0.71, 1.42) but 
trends for bucindolol benefit were observed in several subgroups. Precision therapeutic 
phenotyping revealed that a differential response to bucindolol was associated with: 1) the 
interval of time from the initial diagnosis of HF and AF to randomization, and; 2) the onset of 
AF relative to initial HF diagnosis. In a cohort whose first HF and AF diagnoses were < 12 years 
prior to randomization, in which AF onset did not precede HF by more than 2 years (N=196) the 
HR was 0.54 (95% CI: 0.33, 0.87; p=0.011).  
Conclusion: Pharmacogenetic-guided bucindolol therapy did not reduce the recurrence of 
AF/AFL/ACM compared to metoprolol in HFrEF patients, but populations were identified that 
merit further investigation in future Phase 3 trials.  
 
Key Words: atrial fibrillation; bucindolol; heart failure; beta-blocker; pharmacogenetics; 
precision medicine  
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Atrial fibrillation (AF) is a common and serious medical problem associated with significant 
morbidity and mortality, especially in patients with heart failure (HF) (1). Development of AF is 
associated with increased risk of adverse cardiovascular outcomes, and when AF occurs in 
patients with HF these adverse effects are accentuated (2,3). AF and HF often co-exist and have 
common risk factors, as well as overlapping pathophysiologies (3). Therefore, there is a strong 
rationale to minimize the occurrence of AF in patients with HF. Antiarrhythmic drugs can reduce 
AF burden but have many side effects including proarrhythmia, with many agents being 
contraindicated in HF patients (1). Although catheter ablation shows promise for preventing 
recurrent AF in HF patients with reduced ejection fraction (HFrEF) (4,5), it may not be suitable 
or practical for many patients. Thus, there is an unmet need for safe and effective drugs to reduce 
AF in patients with HF. Beta-blockers are first-line therapy for HFrEF due to their benefits in 
reducing morbidity and mortality and are widely used in HF patients with AF to control 
ventricular response rate. In addition, beta-blockers have modest AF prevention effects in HFrEF 
patients (6).  
Bucindolol is a non-selective beta-blocker with mild vasodilator properties and two unique 
antiadrenergic properties; a moderate sympatholytic effect (7) and inverse agonism for the 
ADRB1 Arg389 major allele gene product (8), a property which promotes inactivation of 
constitutively active beta1-adrenergic receptors. The treatment effects of bucindolol appear to be 
enhanced in patients homozygous for ADRB1 Arg389 (ADRB1 Arg389Arg) (8,9). In advanced 
HFrEF patients with this genotype, a 74% reduction in the development of AF was observed for 
patients in sinus rhythm at baseline who received bucindolol compared to placebo (10). 















ADRB1 Arg389Arg genotype (11,12). Therefore, the GENETIC-AF trial (i.e., G notype-
Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for the Prevention of 
Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure) was designed to 
evaluate the efficacy of a pharmacogenetically-guided rhythm control intervention with 
bucindolol compared to metoprolol for the prevention of AF/AFL in an ADRB1 Arg389Arg 
HFrEF population at risk of AF/AFL recurrence. 
Methods 
Study Design 
GENETIC-AF was a multicenter, randomized, double-blind, comparative efficacy trial in a 
genotype-defined population with HFrEF, defined as a left ventricular ejection fraction (LVEF) 
< 0.50 and AF (Online Supplement). The trial had an adaptive design allowing for seamless 
transition from Phase 2B to Phase 3 based on review of interim data. The rationale and design of 
the trial have been previously reported (13).  
Patients were randomly assigned to receive bucindolol or metoprolol and were up-titrated to 
target doses (Online Table 1). Following up-titration, electrical cardioversion (ECV) was 
performed if needed to establish sinus rhythm prior to the start of follow-up. During the 24-week 
follow-up period, heart rhythm was monitored by 12-lead electrocardiogram (ECG) every 4 
weeks (Online Figure 1). A prospectively defined device substudy permitted continuous heart 
rhythm monitoring to assess AF burden. Substudy participants had a pre-existing Medtronic 
pacemaker or defibrillator with an atrial lead or were implanted with a Medtronic Reveal LINQ 
insertable cardiac monitor (ICM) prior to the start of follow-up. After week 24, patients 
continued to receive blinded study drug and had clinic visits every 12 weeks for assessments of 















Patients had HFrEF with a LVEF < 0.50 assessed in the past 12 months, symptomatic 
paroxysmal or persistent AF in the past 180 days and were receiving optimal anticoagulation 
therapy for stroke prevention. Patients were genotyped at screening and those who were ADRB1 
Arg389Arg were eligible for randomization. 
Exclusion criteria included New York Heart Association (NYHA) Class IV symptoms, 
clinically significant fluid overload, permanent AF (ongoing AF event >1 year), antiarrhythmic 
therapies in past 7 days, prior atrioventricular node ablation, high-grade atrioventricular block, 
catheter ablation for AF or atrial flutter (AFL) in past 30 days, and prior intolerance or 
contraindication to beta-blocker therapy. Details of the trial entry criteria have been previously 
reported (13). 
The active comparator, metoprolol succinate (Toprol-XL), is a selective beta1-adrenergic 
receptor blocker indicated for the treatment of HF. Metoprolol was selected as the active 
comparator to ensure continuity with previous HF trials and because it has demonstrated 
effectiveness in preventing AF in HFrEF patients (14,15), but does not appear to confer 
enhanced benefits in patients with an ADRB1 Arg389Arg genotype (11,12).  
Patients were randomized (1:1) to treatment with bucindolol or metoprolol, which was over-
encapsulated to maintain blinding. Since bucindolol is administered twice-daily (bid), and 
metoprolol is given once-daily (qd), a placebo dose was included for the metoprolol arm and all 
study drugs were administered twice-daily. Randomization was centralized and stratified by HF 
etiology (ischemic, non-ischemic), LVEF (< 0.35, ≥ 0.35), device type (ICM, 
pacemaker/defibrillator, no device), and rhythm at randomization (sinus rhythm, AF/AFL), using 
16,000 randomly generated numbers and a block size of four. Study drug was titrated weekly to 















metoprolol (17). For more details see Online Table 1. Patients experiencing AF/AFL during 
follow-up remained on blinded study drug and could undergo ECV, ablation, or initiate therapy 
with amiodarone or dofetilide. 
ADRB1 Arg389Gly genotype was determined by RT-PCR in DNA extracted from whole 
blood. Systemic venous plasma norepinephrine was assayed by high-pressure liquid 
chromatography with electrochemical detection and venous plasma NT-proBNP was measured 
by electrochemiluminescence immunoassay.  
Study design, conduct, and performance were overseen by a 11-member Steering Committee 
and was monitored by a 3-member Data and Safety Monitoring Committee (DSMB) who also 
performed the interim efficacy analysis (committee composition in Online Supplement). The 
protocol was approved by the Institutional Review Board/Ethics Committee and all patients 
provided written informed consent.  
Statistical Analyses 
For the interim analysis, the endpoint of interest was time to first event of AF/AFL or all-
cause mortality (ACM) during a 24-week follow-up period. The primary endpoint for the 
planned Phase 3 study was time to symptomatic AF/AFL or ACM, with symptoms captured by a 
study-specific questionnaire (Online Supplement). A clinical events committee, blinded to 
treatment assignment, adjudicated the first occurrence of the AF/AFL endpoint, including the 
association of new or worsening symptoms. Sample size for Phase 3 assumed a 60% event rate 
in the metoprolol arm, a 25% relative risk reduction with bucindolol, and accrual of 330 primary 
events in approximately 620 patients for 90% power at alpha=0.01.  
The efficacy analysis was conducted according to intention-to-treat with censoring at 24 















(CI) values were determined by Cox proportional hazards models with adjustment for the four 
randomization strata, and treatment as a covariate. Testing for superiority was performed using a 
2-sided significance level of 0.05. Patients who died prior to start of follow-up and patients who 
failed to establish sinus rhythm post-ECV were assigned an event on day 1. Patients were 
censored on day 1 if they were in AF/AFL and the ECV procedure was not performed, or if they 
withdrew from the study prior to start of follow-up.  
Variables identified in the GENETIC-AF Statistical Analysis Plan (SAP, Online 
Supplement) that were potential predictors of the primary endpoint were investigated by 
precision therapeutic phenotyping. Hypothesis-based (e.g., AF duration, AF type, LVEF, NYHA 
Class, NT-proBNP, norepinephrine) and hypothesis-free (e.g. HF duration, initial study dose) 
elements were included in the multivariate methodology, which was applied to both obvious and 
non-obvious data to identify a therapeutic phenotype appropriate for investigating in Phase 3. To 
examine the relationship between HF duration and bucindolol effectiveness for reducing HF 
events, we analyzed data from the BEST trial (16) and pharmacogenetic substudy (8) for the 
endpoint of time to all-cause mortality or first HF hospitalization (ACM/HFH). 
Time to first event of AF/AFL or ACM was assessed in the device substudy following 
similar methodology for the primary endpoint, with an AF/AFL event prospectively-defined as 
AF burden ≥ 6 hours per day as recorded by continuous monitoring. Six hours of AF burden has 
previously been shown to be associated with an increased rate of hospitalization for HF (18). 
Due to the smaller sample size in the substudy, treatment effect estimates were determined based 
on Cox proportional hazards models with no adjustment for randomization strata. 
Normally distributed continuous variables were analyzed by t-tests or ANOVA where 















Wilcoxon signed rank test, and between group differences by the Wilcoxon rank sum test. 
Categorical variable differences were assessed by Chi square or Fisher’s exact test. 
An interim analysis examined data from the initial Phase 2B population. If the DSMB 
determined that the data were consistent with pre-trial assumptions, the trial was to seamlessly 
proceed to Phase 3 (see Online Supplement for SAP). To aid in signal detection, Bayesian 
predictive probability of success estimates (19,20) were generated and compared to prespecified 
thresholds for each potential outcome (i.e., Phase 3 transition, Phase 2B completion, or futility). 
Based on the interim analysis the DSMB recommended completion of Phase 2B, and the data 
from this population are presented below. 
 
Results 
Population and Baseline Characteristics 
The trial was conducted in 92 centers in 6 countries (Canada, Hungary, The Netherlands, 
Poland, Serbia, and the United States) between April 2014 and December 2017. A total of 760 
patients were screened (Figure 1); 362 (48%) failed screening due to genotype, 73 (9.6%) did 
not meet other eligibility criteria, and 58 (7.6%) failed due to other reasons (e.g., withdrawal of 
consent, lost to follow-up). The remaining 267 patients were randomized to study drug and up-
titrated to target doses. Compliance was >90% in both groups, with a higher proportion of 
patients attaining target dose for bucindolol compared to metoprolol (84% and 72%, 
respectively; p = 0.035).  
Baseline characteristics were well-balanced between treatment groups (Table 1). Mean 
LVEF was 0.36±0.10, 72% had NYHA II or III symptoms at baseline, 51% had persistent AF, 















(IQR): 384, 1420). ECV was required in 46% of patients to establish sinus rhythm prior to 
follow-up start. About half (48%) of all patients had implanted monitoring devices, which 
included ICMs inserted for the trial (16%) and pre-existing pacemakers or defibrillators (32%). 
Efficacy Outcomes 
A total of 143 events were observed for the efficacy endpoint, including 121 AF/AFL events, 
19 ECV failures, and 3 deaths. Nearly all AF/AFL events were adjudicated as symptomatic by a 
blinded clinical events committee (114/121; 94%). Event rates were similar for the bucindolol 
and metoprolol groups (54% and 53%, respectively), with a HR of 1.01 (95% CI: 0.71, 1.42) for 
the covariate-adjusted Cox proportional hazards model (Figure 2). In a prespecified analysis 
(Online Supplement, Statistical Analysis Plan and Phase 2B Amendment) of regional subgroups 
(Table 2, Online Figure 3), a trend for bucindolol benefit compared to metoprolol was observed 
in the U.S. subgroup (HR = 0.70; 95% CI: 0.41, 1.19), which was not seen in Canada (HR = 
1.52; 95% CI: 0.68, 3.43) or in Europe (HR = 1.01; 95% CI: 0.48, 0.48, 2.14).  
Device Substudy  
The device substudy included 69 patients from the U.S. (N=42), Canada (N=21), and Europe 
(n=6) who underwent continuous atrial rhythm monitoring. Cardiac monitors were inserted in 43 
patients for the trial, whereas, 26 patients had pre-existing pacemakers or implantable 
cardioverter defibrillators (ICDs). The baseline characteristics of the substudy were well-
balanced between the two groups and were generally similar to the overall population (T ble 1); 
however, the substudy had a higher proportion of males (93% vs. 82%), persistent AF (64% vs. 
51%), and AF at the time of randomization (65% vs. 51%), compared to the overall population.  
An analysis of time to first event of AF/AFL or ACM was conducted in the device substudy 















bucindolol benefit compared to metoprolol was observed by device-based detection (HR = 0.75; 
95% CI: 0.43, 1.32). Similar results were observed when the substudy population was assessed 
by intermittent, clinic-based 12-lead ECGs (HR = 0.69; 95% CI: 0.38, 1.23); however, the 
device-detected endpoint generally occurred earlier than the ECG-based endpoint (median = 6.5 
days; p < 0.0001). For detection of subsequent ECG-determined AF, AF burden ≥ 6 hours had a 
sensitivity of 100%, a specificity of 87% and an accuracy of 96%. 
Patient Characteristics and Treatment Response by Region 
The differences in treatment response observed in the U.S. and non-U.S. cohorts prompted 
examination of baseline characteristics by region (O line Table 2). In general, the non-U.S. 
cohort had less severe HF compared to the U.S. cohort, as demonstrated by significantly higher 
LVEF (0.39 vs. 0.33), systolic blood pressure (126 v. 120 mmHg), and NYHA class I symptoms 
(39% vs. 17%), as well as significantly lower plasma NT-proBNP (1135 vs. 1380 pg/mL) and 
NYHA class III symptoms (5% vs. 26%). Notably, patients in the non-U.S. cohort had a more 
recent diagnosis of HF (Table 2, Online Table 2), with a mean time from HF diagnosis to 
randomization that was less than half of that in the U.S. group (2.0 vs. 4.5 years); whereas, mean 
time from AF diagnosis to randomization was similar between the two groups (3.8 vs. 3.4 years).  
To quantify the relationship between the initial development of HF and AF, an index termed 
the diagnosis to randomization index (DTRI) was derived from information provided in case 
report forms. This index represents the differences between the HF duration (i.e., the time of HF 
diagnosis to randomization) and the AF duration (i.e., the time of AF diagnosis to 
randomization), with positive values representing HF onset prior to AF and negative values 
representing AF onset prior to HF. As shown in Table 2, the U.S. and non-U.S. cohorts had 















(p < 0.0005). The U.S. cohort, on average, had HF for more than a year prior to developing AF; 
whereas, the non-U.S. cohort had a diagnosis of AF for nearly 2 years prior to developing HF. 
Interestingly, bucindolol response for the primary endpoint correlated with mean DTRI 
(ρ = -0.93, p = 0.020), with poor response seen in populations having long-standing AF prior to 
the development of HF (i.e., Hungary and Canada) and good response in populations with 
concurrent or previous onset of HF prior to the development of AF (i.e., U.S., Poland, and 
Serbia). 
Baseline Characteristics Predicting Endpoint Frequency and/or Interaction with Treatment  
Cox proportional hazards regression modeling was performed to explore prespecified 
variables (SAP, Online Supplement) that were potential predictors of the primary endpoint 
(Online Table 3). Three variables violated the Cox model proportionality of hazards assumption. 
Of these, atrial rhythm at randomization was previously addressed by randomization 
stratification, as was heart rate, which generally correlates with atrial rhythm. The third variable, 
prior treatment with class III anti-arrhythmic drugs, was not previously identified and was 
included as a covariate in all subsequent analyses to account for non-proportional influence on 
baseline hazard.  
On multivariate analysis, ten variables predicted the occurrence of the primary endpoint. In 
addition to the initial dose of study drug, which was based on beta blocker therapy prior to 
enrollment, the two-predictor model identified five variables related to the degree or duration of 
HF (i.e., systolic blood pressure, HF duration, HF etiology, NT-proBNP, and NYHA Class) and 
four variables related to heart rhythm (i.e., rhythm at randomization, baseline heart rate, AF type, 
and the number of prior ECVs). The only predictor by treatment interaction variable having a p-















The time from initial HF diagnosis to randomization (i.e., HF DxT) was a significant 
predictor for the occurrence of primary endpoint but did not predict treatment or treatment by 
predictor interactions in Cox modeling of the primary endpoint (O line Table 3). However, 
since AF DxT predicted bucindolol response for the prevention of AF recurrence, we examined 
data from the placebo-controlled BEST HF trial (16) to determine whether HF DxT had a similar 
relationship to bucindolol response for the HF endpoint, ACM or first HF hospitalization (HFH). 
As shown in Online Figure 3, an attenuation of treatment response for the BEST ACM/HFH 
endpoint is observed in cohorts with greater values of HF DxT upper bound (i.e., inclusion of 
long-standing HF prior to randomization). This strong, negative correlation was observed in both 
the entire cohort (N = 2708; r = -0.82; 95% CI: -0.92, -0.59) and for the ADRB1 Arg389Arg 
subgroup (N = 493; r = -0.79; 95% CI: -0.91, -0.54).  
Effect of Duration and Relative Onset of AF and HF on Treatment Effect  
To further examine the effects of AF and HF duration identified in the above analyses, a 
3-dimensional plot was constructed with treatment effect (i.e., 1-hazard ratio) for the GENETIC-
AF primary endpoint as the dependent variable (z-axis), and HF DxT (x-axis) and AF DxT (y-
axis) as independent variables. As shown in the Central Illustration (A), an attenuation of 
treatment effect was associated with increasing values of both AF and HF DxT. When equivalent 
DxT values (both HF and AF DxT values had to be < the timepoint duration on the x axis) were 
used to examine the combined effects of AF and HF duration (Online Figure 4), a strong 
negative correlation was observed (r = -0.94; 95% CI: -0.97, -0.89), with substantial attenuation 
of treatment effect seen with the inclusion of a small proportion of patients with both AF and HF 















To examine the effects of the r lative onset of AF and HF on treatment effect, a 
3-dimensional plot was constructed with treatment effect as the dependent variable (z-axis), and 
the absolute value of DTRI lower bound (i.e., years of AF prior to HF) and DTRI upper bound 
(i.e., years of HF prior to AF) and as independent variables. As shown in Central Illustration 
(B), there is an attenuation of treatment effect associated with increasing absolute values of 
DTRI lower and upper bound (i.e., increasing time between the initial presentations of AF and 
HF). When equivalent absolute values for DTRI lower and upper bounds were used to examine 
the concept of contemporaneous AF and HF development (Online Figure 5A), there was a 
nearly linear, negative correlation with treatment effect (r = -0.96; 95% CI: -0.98, -0.92).  
Prevention of AF Recurrence in the Precision Therapeutic Selected Phenotype 
Duration and relative onset of AF and HF are indirectly related characteristics that may have 
additive and/or overlapping effects. Therefore, we examined their use in combination to identify 
a precision therapeutic phenotype appropriate for further study. Details of the precision 
therapeutic phenotype analyses are presented in the Online Supplement.  
 In the example presented below, we selected a population with an AF and HF DxT < 12 
years (i.e., DxT12 cohort), as this cutoff retained a high proportion (86%) of the overall 
population while minimizing attenuation of the observed treatment effect. We then applied a 
DTRI lower bound of -2 years (i.e., AF not preceding HF by more than 2 years; DxT12/DTRI-2 
cohort), as this cutoff retained 85% of the DxT12 cohort. As shown in Online Figure 6, 
restriction of DTRI upper bound (i.e., years of HF prior to AF) was not required when examined 
in a DxT12 background.  
Patient characteristics of the DxT12 and DxT12/DTRI-2 cohorts are shown in O li e Table 















and HF; whereas the population excluded by the DTRI > -2 years criteria had characteristics 
consistent with longstanding AF as primary diagnosis and treatment history, with primarily mild 
left ventricular dysfunction. Of note, patients who had contemporaneous development of both 
AF and HF (i.e., DTRI values within 2 years of zero) are the majority of those included in the 
230 patient DxT12 cohort (“DTRI included”); whereas DTRI patients with values ±2 years are 
conspicuously absent from the 37 patient cohort excluded by the DxT12 criteria, i.e. those with 
the first diagnosis of both AF and HF ≥12 years prior to randomization (Online Figure 5B). The 
accumulation of a substantial number (> 10) of patients with DTRI values ±2 years does not 
occur until the DxT cutoff is restricted to < 6 years (data not shown). 
The primary endpoint of time to first event of AF/AFL/ACM for the DxT12/DTRI-2 cohort 
(N=196) is shown in Figure 4. In HFrEF patients (LVEF < 0.50) the HR was 0.54 (95% CI: 
0.33, 0.87) by ECG-based detection, with similar results observed by device-based detection (HR 
= 0.59; 95% CI: 0.30, 1.19; N=49). In HF patients with mid-range ejection fraction (HFmrEF; 
LVEF ≥ 0.40 and < 0.50) the HR was 0.42 (95% CI: 0.21, 0.86; p = 0.017) and in HF patients 
with lower-range ejection fraction (HFlrEF; LVEF < 0.40) the HR was 0.69 (95% CI: 0.33, 1.43; 
p = 0.32). Device-based estimate for HFmrEF and HFlrEF are not presented due to the small 
sample size. See Online Table 5 for more details. 
Effects on Norepinephrine and NT-proBNP 
Plasma norepinephrine at baseline was similar in the bucindolol (682 ± 348 pg/ml, n=128) 
and metoprolol (664 ± 359 pg/ml, n=134) groups. At 4 weeks, there was a significant decrease 
from baseline in the bucindolol group (-124 ± 26 pg/ml; p < 0.001) that was not observed in the 
metoprolol group (-36 ± 32 pg/ml; p = 0.30). The change from baseline at 4 weeks was 















Plasma NT-proBNP was non-normally distributed in both groups, and median values at 
baseline were similar (777 and 861 pg/ml, p = 0.38; Online Table 6). There was a significant 
decrease from baseline in the bucindolol group at week 4 (-96 pg/ml; p = 0.003) and week 12 
(-96 pg/ml; p =0.002) that was not observed in the metoprolol group. At week 24, significant 
decreases relative to baseline values were observed in both the bucindolol (-197 pg/ml; p = 
0.005) and metoprolol (-100 pg/ml; p = 0.014) groups, but the change from baseline was not 
significantly different between the two groups (p = 0.220). 
Safety 
The proportion of patients experiencing adverse events (AEs) was similar in the two groups 
(Table 3). More patients in the metoprolol group had symptomatic bradycardia or bradycardia 
leading to dose reduction or discontinuation of study drug compared to the bucindolol group 
(9.0% vs. 3.0%; p=0.042). Three (2.3%) patients in each group died while receiving study drug 
or within 30 days of their last dose. All deaths in the metoprolol group occurred during the 
primary endpoint period (worsening HF − day 25; sudden cardiac death − day 43; motor vehicle 
accident − day 77). All deaths in the bucindolol group occurred during the long-term extension 
period (respiratory failure − day 385; sudden death − day 535; cardiac tamponade − day 779). 
Rates of HF hospitalization (7.5% vs. 8.3%) and ACM/HF hospitalization (8.2% vs. 9.0%) were 
similar for the bucindolol and metoprolol groups, respectively. There were no strokes in either 
treatment group, with 93% of patients receiving oral anticoagulants prior to randomization. 
 
Discussion 
The GENETIC-AF trial was designed as an adaptive, randomized, controlled trial that was 















suggested efficacy was likely on expansion to the Phase 3 sample size (9). In the Phase 2B 
analysis, pharmacogenetic-guided bucindolol did not reduce the recurrence of AF/AFL/ACM 
compared to metoprolol in the overall population. However, trends for bucindolol benefit were 
observed in key subgroups, particularly in those without long-standing and heavily treated AF 
prior to the development of HF. A lower proportion of patients with longstanding AF diagnosed 
prior to the development of HF likely contributed to the favorable bucindolol treatment effect in 
U.S. and device substudy patients, who were majority U.S. enrolled. In addition to the findings 
relevant to the investigational drug, this study also has several important findings relative to 
detection of AF in clinical trials.  
GENETIC-AF also represents several firsts in the conduct of pharmacogenetic studies in 
cardiovascular disease and AF in particular. It is the first pharmacogenetically-targeted, 
randomized, controlled trial of rhythm control therapy in AF. Moreover, it is the first 
pharmacogenetic trial for prevention of recurrent AF in HFrEF, defined as HF with any decrease 
in LVEF (23). It is also the first study to compare AF burden to symptomatic AF/AFL as 
determined by adjudication of symptoms and ECG data. Finally, it represents the first 
comparative beta-blocker trial to include HF patients with mid-range ejection fraction 
(HFmrEF), defined as a LVEF ≥ 0.40 and < 0.50 (24). 
There are several important findings from GENETIC-AF regarding AF in this HFrEF 
population. For example, nearly all patients who experienced AF recurrence had symptomatic 
AF, defined as new or worsening symptoms as adjudicated by a blinded clinical events 
committee. Recently, there has also been considerable interest in methods of AF diagnosis in 
clinical practice, including telemetry and device-based technologies (21,22). Our device 















burden had previously been shown to be associated with an increased rate of hospitalization for 
HF (18). We found that AF burden ≥ 6 hours per day as recorded by continuous monitoring 
exhibited high predictive accuracy for clinically symptomatic AF/AFL and tended to identify 
these events earlier than intermittent ECG monitoring. 
Approximately half of patients screened for this trial had the ADRB1 Arg389Arg genotype, 
consistent with previous findings (8-11). In this genotype only norepinephrine high affinity beta1 
Arg389 receptors are present, providing a substrate for the favorable effect of sympatholysis (9) 
that was again observed for bucindolol. Bucindolol lowered plasma norepinephrine levels after 4 
weeks of treatment, which was not observed for metoprolol. Plasma NT-proBNP levels also 
decreased significantly with bucindolol treatment but not with metoprolol. These data indicate 
that the pharmacodynamic profile that contributes to the pharmacogenetic differentiation of 
bucindolol was operative in the trial.  
It is also notable there were no safety concerns identified with bucindolol. Similar rates of 
death and hospitalization were observed in both treatment arms, though power was limited for 
detection of uncommon events. Interestingly, bradycardia was significantly lower in the 
bucindolol arm, suggesting that bucindolol may lead to less bradycardia than metoprolol in 
patients with the ADRB1 Arg389Arg genotype.  
A major goal of a Phase 2 clinical trial is to further refine the study population that will be 
investigated in Phase 3. To this end we conducted an exercise in precision therapeutic 
phenotyping, or “individual treatment effect modeling” (23), designed to identify both 
prespecified obvious as well as nonobvious variables associated with a beneficial treatment 
effect of bucindolol. Exploration of factors contributing to the heterogeneity in response 















randomization and relative to one another. This led us to identify two variables that were 
strongly associated with an attenuation of bucindolol response: 1) the interval of time from the 
initial diagnosis of HF and AF to randomization (i.e., DxT), and; 2) the onset of AF relative to 
initial HF diagnosis (i.e., DTRI). AF duration has previously been reported to modulate response 
for other drug therapies post-ECV (24) and for catheter ablation (25). Less well appreciated is 
how the HF duration may impact medical therapy, and how these two variables interact in HF 
patients with concomitant AF. It should also be noted that GENETIC-AF compared two 
members of a drug class that had been administered chronically to this population, in some cases 
for years, prior to randomization. As such, a survivor effect due to loss of patients who develop 
AF and HF within a few years of each other, potentially due to adverse effects on mortality with 
the combination (26), may be responsible for altering the composition of certain subpopulations 
(i.e., those with longstanding AF/HF DxT, Online Figure 5B) in a manner that influences 
treatment response (Online Figure 6). If a contemporaneous relationship between the onset of 
AF and HF is optimal for bucindolol to maintain sinus rhythm, potentially related to higher 
levels of adrenergic activity when both conditions manifest in some proximity (10, 26), then this 
would explain the phenotype identified in our analysis. Alternatively, or in addition, it is also 
possible that the DTRI effect has a biological origin based on differences in atrial and ventricular 
pathophysiology when AF precedes or dominates over HF, the major difference residing in 
chamber interstitial fibrosis being a more prominent feature in AF (27, 28).  
For comparative efficacy studies that seek to observe a differential response between two 
drugs in the same drug class it is critical to identify a study population with high potential for 
overall response to the drug class. This is necessary because a differential response is, by 















observe in a given study population. In this exploratory Phase 2 trial with limited sample size 
and statistical power, we identified HF populations who respond differentially to two beta-
blockers based on genetic targeting. This approach circumvents potential issues associated with 
conventional subset analyses by evaluating monotonicity and consistency of trends across the 
full continuum of candidate variables such that the classifiers are readily conducive to numerical 
calibration (examples provided in Online Supplement). We propose that increasing the 
permissible limits of variation (i.e., tolerance) for the phenotype selection criteria increases the 
likelihood of reproducibility of these results in future studies. 
Limitations 
The results of this Phase 2B trial are best considered in light of its limitations. Given the 
conclusion of the study at Phase 2B, there was not adequate power to definitively test 
superiority. Although AF DxT and HF DxT were prespecified in the SAP prior to unblinding as 
potential predictors of treatment response, the onset relationship derived from these variables 
(i.e., DTRI) was retrospectively defined. Multiplicity via subgroup analysis can lead to false 
discovery, although this was tempered by examination for consistent trends across the entire 
dataset and other comparable datasets (i.e. BEST). Lastly, the selection of the precision 
therapeutic phenotype was based on response, but also considered the sample size needed to 
maintain feasibility for enrollment in future trials. As such, the treatment effect estimates derived 
from these analyses are hypothesis generating only and will need to be evaluated in a subsequent, 
prospectively-designed trial. 
Conclusion  
In the first trial of a pharmacogenetic-guided rhythm control intervention, bucindolol did not 















However, precision therapeutic phenotyping identified a large population of HF patients with an 
ADRB1 Arg389Arg genotype who display a differential response to bucindolol compared to 
metoprolol for the prevention of AF/AFL. This experience underscores the utility of performing 
relatively large Phase 2 studies comprised of heterogeneous populations in order to generate the 















Competency in Medical Knowledge 
The intersection of atrial fibrillation (AF) and heart failure (HF) is common, worsens the 
prognosis of each disorder and lacks effective, easily administered and safe drug therapy. In the 
BEST trial pharmacogenetic substudy, against placebo in patients with an ADRB1 Arg389Arg 
genotype the 4th generation beta-blocker bucindolol reduced the risk of developing AF by 74%, 
leading to design and performance of the Phase 2 trial GENETIC-AF where 267 high AF risk 
HFrEF patients were randomized to bucindolol vs. the conventional, 2nd generation compound 
metoprolol succinate. Overall there was no difference in effectiveness (hazard ratio (HR) 1.01; 
95% CI: 0.71, 1.42), but a trend for benefit with bucindolol was observed in the U.S. subgroup 
(N=127; HR=0.70; 95% CI: 0.41, 1.19) and in patients with implanted devices (N=69; HR=0.75; 
95% CI: 0.43, 1.32). The trial exhibited marked regional heterogeneity, which was attributed to 2 
countries predominately enrolling patients whose AF diagnosis preceded HF by many years; in 
countries that enrolled patients with a more contemporaneous presentation of AF and HF 
bucindolol was associated with a positive efficacy signal. 
 
Translational Outlook 
The theoretical basis for bucindolol’s advantage over conventional beta-blockers for preventing 
AF and reducing HF events in HFrEF patients who are genotype ADRB1 Arg389Arg is its more 
powerful inhibition of the higher functioning Arg389 polymorphic variant of the beta1-
adrenergic receptor. The ADRB1 Arg389Gly polymorphism is not present in other species but 
can be and has been investigated by transgenic overexpression in mice. In terms of the potential 
for reverse translation, precision therapeutic phenotyping in GENETIC-AF identified a group of 















bucindolol, suggesting different pathophysiology compared to patients who develop AF and HF 
contemporaneously. This putative pathophysiologic difference and its impact on therapy, 
potentially related to a greater burden of atrial and ventricular fibrosis associated with 




















1. Trulock KM, Narayan SM, Piccini JP. Rhythm control in heart failure patients with atrial 
fibrillation: contemporary challenges including the role of ablation. J Am Coll Cardiol 
2014;64:710-21. 
2. Olsson LG, Swedberg K, Ducharme A et al. Atrial fibrillation and risk of clinical events 
in chronic heart failure with and without left ventricular systolic dysfunction: results from 
the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity 
(CHARM) program. J Am Coll Cardiol 2006;47:1997-2004. 
3. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and 
congestive heart failure and their joint influence on mortality: the Framingham Heart 
Study. Circulation 2003;107:2920-5. 
4. Turagam MK, Garg J, Whang W et al. Catheter Ablation of Atrial Fibrillation in Patients 
With Heart Failure: A Meta-analysis of Randomized Controlled Trials. Ann Intern Med. 
2019;170(1):41-50.. 
5. Marrouche NF, Brachmann J, Andresen D et al. Catheter Ablation for Atrial Fibrillation 
with Heart Failure. N Engl J Med 2018;378:417-427. 
6. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of 
atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur 
Heart J 2007;28:457-62. 
7. Bristow MR, Krause-Steinrauf H, Nuzzo R et al. Effect of Baseline or changes in 
adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial 















8. Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al. A polymorphism within a highly 
conserved β1-adrenergic receptor motif alters beta-blocker response in multiple models 
and human heart failure. Proc Natl Acad Sci 2006;103:11288-93. 
9. O’Connor CM, Fiuzat M, Carson PE et al. Combinatorial pharmacogenetic interactions 
of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PLoS One 
2012;7:e44324 
10. Aleong RG, Sauer WH, Davis G, et al. Prevention of atrial fibrillation by bucindolol is 
dependent on the beta-1 389 Arg/Gly adrenergic receptor polymorphism. JACC Heart 
Fail 2013;1:338-44. 
11. Sehnert AJ, Daniels SE, Elashoff M et al. Lack of association between adrenergic 
receptor genotypes and survival in heart failure patients treated with carvedilol or 
metoprolol. J Am Coll Cardiol 2008;52:644-51. 
12. White HL, de Boer RA, Maqbool A et al. An evaluation of the beta-1 adrenergic receptor 
Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur 
J Heart Fail 2003;5:463-8. 
13. Piccini JP, Connolly SJ, Abraham WT et al. A genotype-directed comparative 
effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic 
atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the 
GENETIC-AF trial. Am Heart J 2018;199:51-58. 
14, van Veldhuisen DJ, Aass H, El Allaf D, Dunselman PH, Gullestad L, Halinen M, 
Kjekshus J, Ohlsson L, Wedel H, Wikstrand J and Group M-HS. Presence and 
development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-















15. Nergårdh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with 
metoprolol CR initiated before cardioversion and repeated cardioversion of atrial 
fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J 
2007;28:1351-7. 
16. BEST Investigators. Beta-Blocker Evaluation of Survival Trial I. A trial of the beta-
blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 
2001;344:1659-67. 
17. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: 
Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-
HF). Lancet 1999;353:2001-7. 
18. Sarkar S, Koehler J, Crossley GH et al. Burden of atrial fibrillation and poor rate control 
detected by continuous monitoring and the risk for heart failure hospitalization. Am Heart 
J 2012;164:616-24. 
19. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or 
predictive power? Control Clin Trials. 1986;7(1):8-17. 
20. Berry SM, Spinelli W, Littman GS, Liang JZ, Fardipour P, Berry DA, Lewis RJ, Krams 
M. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy 
and safety of an investigational drug. Clin Trials. 2010;7:121-35. 
21. Steinhubl SR, Waalen J, Edwards AM et al. Effect of a Home-Based Wearable 
Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The 















22. Turakhia MP, Desai M, Hedlin H et al. Rationale and design of a large-scale, app-based 
study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. Am 
Heart J 2019;207:66-75. 
23, Wilson FP, Parikh CR. Translational Methods in Nephrology: Individual Treatment 
Effect Modeling. Am Soc Nephrol. 2018;29:2615-18. 
24. Toso E, Blandino A, Sardi D, Battaglia A, Garberoglio L, Miceli S, Azzaro G, Capello 
AL, Gaita F. Electrical cardioversion of persistent atrial fibrillation: acute and long-term 
results stratified according to arrhythmia duration. Pacing Clin Electrophysiol 
2012;35:1126-34. 
25. Bunch TJ, May HT, Bair TL, et al. Increasing time between first diagnosis of atrial 
fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm 
2013;10:1257-62. 
26. Aleong RG, Sauer WH, MD, Davis G, Bristow MR. New onset atrial fibrillation predicts 
heart failure progression. Am J Med. 2014;127:963-71. 
27. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in 
dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95. 
28. Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With 


















CENTRAL ILLUSTRATION Treatment Effect by Duration and Relative Onset of AF and 
HF prior to Randomization  
A. 3-dimensional plot of HF DxT (x-axis) and AF DxT (y-axis) versus treatment effect (z-axis).  
B. 3-dimensional plot of AF onset prior to HF (x-axis) and HF onset prior to AF (y-axis) versus 
treatment effect (z-axis). Hazard ratio is for time to AF/AFL/ACM endpoint. HF DxT=time from 
initial HF diagnosis to randomization. AF DxT=time from initial AF diagnosis to randomization.  
DTRI (Diagnosis to Randomization Index) = HF DxT – AF DxT. AF onset prior to HF = 
absolute value of DTRI lower bound. HF onset prior to AF = DTRI upper bound. 
 
 
FIGURE 1 Consort Diagram 




FIGURE 2 Time to First AF/AFL/ACM Event  
Cox proportional hazards model adjusted for the four randomization strata.  
Non-stratified hazard ratio = 0.96 (95% CI: 0.69, 1.33). Stratified analysis including adjustment 
for previous use of class III anti-arrhythmic drugs (yes/no): HR = 0.92 (95% CI: 0.63, 1.33). 
 
 
FIGURE 3 Time to First Event of AF/AFL/ACM in the Device Substudy 
A. Device-based detection. B. ECG-based detection. For device-based detection an AF/AFL 




FIGURE 4 Time to First Event of AF/AFL/ACM in the DxT12/DTRI-2 Cohort 
A. ECG-based detection in the entire cohort. B. Device-based detection in the substudy cohort. 



















TABLE 1  BASELINE CHARACTERISTICS     
 Entire Study Device Substudy 
Parameter  All Patients N = 267 
Bucindolol 
N = 134 
Metoprolol 
N = 133 
All Patients 
N = 69 
Bucindolol 
N = 35 
Metoprolol 
N = 34 
Age, years 65.6 ± 10.1 65.8 ± 10.3 65.5 ± 10.0 66.1 ± 10.7 65.5 ± 11.5 66.8 ± 9.9 
Male/Female, % 82/18 83/17 81/19 93/7 94/6 91/9 
Race: W/B/A/O, % 96/2/1/1 96/1/1/2 96/2/1/1 96/1/1/2 94/0/3/3 97/3/0/0 
LVEF 0.36 ± 0.10 0.36 ± 0.10 0.36 ± 0.10 0.34 ± 0.08 0.33 ± 0.08 0.36 ± 0.09 
NYHA I/II/III, % 28/57/15 30/60/10 26/54/20 23/57/20 29/49/23 18/65/18 
Ischemic/Non-Ischemic HF, % 32/68 31/69 33/67 28/72 29/71 26/74 
Randomized in AF/Not in AF, % 51/49 49/51 52/48 65/35 63/37 68/32 
Persistent/Paroxysmal AF, %  51/49 51/49 51/49 64/36 63/37 65/35 
HF DxT Duration, days 1153 ± 1909 1252 ± 2070 1054 ± 1733 1168 ± 1723 1208 ± 1880 1126 ± 1572 
AF DxT Duration, days 1306 ± 2240 1431 ± 2271 1180 ± 2209 1355 ± 1984 1444 ± 1997 1263 ± 1995 
Systolic blood pressure, mm Hg 123.3 ± 15.3 124.7 ± 14.9 121.8 ± 15.7 123.3 ± 15.1 122.4 ± 15.7 124.2 ± 14.5 
Diastolic blood pressure, mmHg 75.3 ± 10.8 75.8 ± 11.0 74.8 ± 10.6 75.0 ± 10.1 73.7 ± 9.9 76.3 ± 10.3 
Heart Rate, bpm 76.3 ± 17.8 76.5 ± 17.9 76.0 ± 17.7 78.4 ± 17.2 76.8 ± 16.4 80.1 ± 18.1 
Previous ECV/AF Ablation/Type III 
AAD, % 
49/21/48 49/21/50 50/20/46 55/13/54 57/17/57 53/9/50 
Device Type: ICM/PM/ICD, % 16/17/15 17/15/18 15/20/12 62/22/16 66/20/14 59/24/18 
Norepinephrine, pg/ml 673 ± 353 682 ± 348 664 ± 359 706 ± 368 710 ± 398 702 ± 339 













W/B/A/O=White/Black/Asian/Other. HF DxT Duration=time from HF diagnosis to randomization. AF DxT Duration=time from AF 
diagnosis to randomization. ECV=electrical cardioversion. AAD=antiarrhythmic drug. ICM=insertable cardiac monitor. ICD=implanted 
















TABLE 2  Timing of HF and AF Onset Relative to Randomization 
 
Cohort 
HF DxT  
(years) 
AF DxT  
(years) 
DTRI 
(years) Time to AF/AFL/ACM 
Mean Median Mean Median Mean Median P value* 
Stratified 
HR (95% CI) 
Non-stratified 
HR (95% CI) 



































     Netherlands (N=4) 8.0 7.1 6.4 3.8 1.6 -0.1 ND ND ND 
AF DxT=time from AF diagnosis to randomization. HF DxT=time from HF diagnosis to randomization.  
DTRI=diagnosis to randomization index; DTRI=HF DxT – AF DxT.  























Any adverse event (AE) 100 (74.6%) 95 (71.4%) 
AE possible/probably related to study drug 32 (23.9%) 40 (30.1%) 
AE leading to permanent study drug discontinuation  11 (8.2%) 11 (8.3%) 
AE leading to study withdrawal (excluding death) 2 (1.5%) 2 (1.5%) 
AE of symptomatic bradycardia or bradycardia leading to dose 
reduction or discontinuation of study drug 
4 (3.0%) 12 (9.0%) 
Any serious adverse event 34 (25.4%) 27 (20.3%) 
AE leading to death 3 (2.3%) 3 (2.3%) 



















































































































FIGURE 1. GENETIC-AF Study Visit Schedule  
Note: ECV performed 3 weeks after randomization, if needed. Week 0 for patients in SR at randomization is 
3 weeks (± 3 days). S = Screening Visit; R = Randomization Visit; W = week; ECV = electrical cardioversion;  


















A. B. C. 
   
     Number at Risk 
Week 0 8 16 24 
BUC 60 33 30 20 
MET 67 29 23 21 
 
   Number at Risk 
Week 0 8 16 24 
BUC 32 16 13 8 
MET 27 15 12 10 
 
    Number at Risk 
Week 0 8 16 24 
BUC 42 26 21 11 
MET 39 24 20 10 
 
FIGURE 2   Time to First AF/AFL/ACM Event by Region   
A., U.S. cohort; B., Canada cohort; C., Europe cohort.  


























FIGURE 3   Treatment Effect and the Duration of HF in the BEST HF Trial 
Entire cohort (open circles, n=2708) and ADRB1 Arg389Arg subgroup (closed circles, n=493).  
Hazard ratio is for time to first heart failure hospitalization or death for bucindolol and placebo. 
HF DxT=time from initial HF diagnosis to randomization. Rxy=correlation coefficient. 

















FIGURE 4   Treatment Effect by AF and HF Duration 
Treatment effect versus AF/HF DxT (i.e., both HF DxT and AF DxT< X years).  
Hazard ratio is for time to AF/AFL/ACM endpoint. AF/HF DxT= time from initial AF and HF 






















FIGURE 5   Treatment Effect Relationship to Relative Onset of AF and HF (DTRI) 
A. Treatment effect versus absolute value of DTRI upper and lower bounds.   
B. Histogram of DTRI distribution for DxT12 cohort and cohort excluded by DxT12 criteria.  
Hazard ratio is for time to AF/AFL/ACM endpoint. DTRI=Diagnosis to Randomization Index.  




















FIGURE 6   Treatment Effect and the Relative Onset of AF and HF in DxT12 Cohort 
3-dimensional plot of AF onset prior to HF (x-axis) and HF onset prior to AF (y-axis) versus treatment 
effect (z-axis) in DxT12 Cohort. Hazard ratio is for time to AF/AFL/ACM endpoint. DTRI (Diagnosis 
to Randomization Index) = HF DxT – AF DxT. AF onset prior to HF = absolute value of DTRI lower 



















TABLE 1. Study Drug Titration Schedule 



























> ≤ > ≤ > ≤ > ≤ > ≤ > ≤ = = 
- 50 - 25 - 20  6.25 - 2.5 - 1.25 25  6.25 
50 100 25 50 20 40 6.25 12.5 2.5 5 1.25 2.5 50 12.5 
100 200 50 100 40 80 12.5 25 5 10 2.5 5 100  25 
2003 - 1003 - 803 - 253 - 103 - 5 103 200 50 
- - - -   - -   - - 200 1002 
Transition to Starting Dose of Study Drug  Up-titration  
1Transition from β-blockers other than those above requires approval from the Sponsor or its designee prior to randomization. 
2Patients who weigh < 75 kg at randomization will receive a maximum bucindolol dose of 50 mg BID. 
3Patients receiving commercial β-blocker doses higher than those currently approved will require pre-approval from the 






















N = 127 
Non-U.S. 
Cohort 
N = 140 
P-value 
Age, years 66.3 ± 10.7 65.1 ± 9.5 0.516 
Male/Female, % 87/13 78/22 0.079 
Race: W/B/A/O, % 93/4/1/2 99/0/1/0 0.017 
LVEF 0.33 ± 0.09  0.39 ± 0.09 <0.001 
NYHA I/II/III, %  17/57/26 39/56/5 <0.001 
Ischemic/Non-Ischemic HF, % 31/69 33/67 0.896 
Randomized in AF/Not in AF, % 59/41 43/57 0.010 
Persistent/Paroxysmal AF, %  52/48 50/50 0.807 
AF DxT Duration, days 1236 ± 2192 1370 ± 2288 0.517 
HF DxT Duration, days 1627 ± 2306 724 ± 1326 <0.001 
Systolic blood pressure, mm Hg 119.9 ± 15.7 126.3 ± 14.4 0.001 
Diastolic blood pressure, mmHg 73.8 ± 11.3 76.6 ± 10.2 0.024 
Heart Rate, bpm 78.4 ± 19.4 74.4 ± 16.0 0.118 
Previous ECV, % 55 44 0.041 
Previous AF Ablation, % 17 24 0.373 
Previous Type III AAD use, % 47 49 0.902 
Device Type: ICM/PM/ICD, % 19/15/21 14/20/9 0.002 
Norepinephrine, pg/ml 657 ± 373 687 ± 335 0.389 
NT-proBNP, pg/ml, median (IQR) 953 (488, 1506) 678 (143, 1252) 0.045 
W/B/A/O = White/Black/Asian/Other. AF DxT = time from AF diagnosis to randomization. HF DxT = 
time from HF diagnosis to randomization. ECV = electrical cardioversion. AADs = antiarrhythmic 
drugs. ICM = insertable cardiac monitor. ICD = implanted cardiac defibrillator. PM = pacemaker. IQR = 
interquartile range. Note: mean ± standard deviations are presented unless otherwise specified. Wilcoxon 






















TABLE 3. Cox Proportional Hazards Regression Modeling for Time to First AF/AFL/ACM Event  
Predictor 
Two Predictor Model Three Predictor Model 





 0.83   <0.001* 0.66  <0.001* 0.51 
Baseline heart rate
†
 0.80   <0.001* 0.96    0.042* 0.99 
AF type 0.72     0.001* 0.77 0.06 0.49 
Baseline systolic blood pressure 0.84     0.006* 0.15 0.63 0.15 
HF DxT 0.77     0.007* 0.66 0.63 0.73 
Initial study dose  0.39     0.017* 0.79 0.89 0.35 
Prior ECV count 0.76     0.018* 0.37 0.78 0.30 
HF etiology  0.81     0.023* 0.91   0.04* 0.53 
Baseline NT-proBNP 0.91     0.040* 0.48 0.75 0.28 
Baseline NYHA class 0.99     0.043* 0.59 0.91 0.57 
AF DxT 0.83 0.07 0.18 0.14       0.025** 
Device strata 0.72 0.11 0.98 0.77 0.77 
Prior ECV or ablation 0.79 0.13 0.51 0.13 0.52 
Region 0.82 0.09 0.87 0.16 0.33 
Baseline diastolic blood pressure 0.71 0.28 0.18 0.09 0.16 
Previous use of class III AAR
†
 0.76 0.35 0.58 0.32 0.64 
Beta blocker prior to randomization 0.84 0.42 0.66 0.68 0.98 
Baseline creatinine 0.82 0.48 0.30 0.19 0.26 
Total prior ECV or ablation 0.74 0.52 0.75 0.64 0.93 
Prior ablation 0.78 0.62 0.83 0.14 0.19 
LVEF 0.80 0.66 0.79 0.96 0.84 
LVEF strata 0.80 0.68 0.74 0.89 0.82 
CYP2D6 0.98 0.93 0.21 0.29 0.17 
Baseline norepinephrine 0.73 0.99 0.63 0.73 0.72 
*P<0.05 for prediction of primary endpoint. **P<0.05 for treatment x predictor interaction. †Violation of proportionality 
of hazards assumption (p<0.05). AF DxT=time from initial AF diagnosis to randomization. HF DxT=time from initial 
HF diagnosis to randomization. ECV=electrical cardioversion. AAR=antiarrhythmic drug. LVEF=left ventricular 



















TABLE 4. Baseline Characteristics for Selected Phenotypes 
Parameter  











Age, years 64.9 ± 10.2 70.1 ± 8.4 0.012 65.2 ± 9.9 63.1 ± 11.8 0.435 
Male/Female, %  80/20 95/5 0.036 80/20 79/21 1.000 
Race: W/B/A/O, %  97/2/0/1 95/0/0/5  0.087 96/2/1/1 97/3/0/0 0.728 
LVEF 36.6 ± 9.4  33.4 ± 10.5  0.104 36.0 ± 9.3 39.8 ± 9.6 0.010 
NYHA I/II/III, %  30/57/13  6/59/24  0.099 28/57/15 41/56/3 0.074 
Ischemic/Non-Ischemic HF, % 30/70  43/57  0.132 32/68 21/79 0.227 
Randomized in AF/Not in AF, % 47/53 73/27 0.004 48/52 41/59 0.577 
Persistent/Paroxysmal AF, %  49/51  62/38  0.159 48/52 56/44 0.459 
AF DxT, days 770 ± 983 4642 ± 4201 <0.001 539 ± 787 2098 ± 955 <0.001 
HF DxT, days 698 ± 1012 3988 ± 3289 <0.001 778 ± 1064 231 ± 402 <0.001 
Systolic blood pressure, mm Hg 124.0 ± 15.0  118.9 ± 16.7  0.094 123.9 ± 15.4 124.5 ± 13.1 0.827 
Diastolic blood pressure, mmHg 75.7 ± 10.2 72.6 ± 13.7 0.090 75.3 ± 10.4 78.0 ± 9.3 0.093 
Heart rate, bpm 76.2 ± 18.3 76.6 ± 14.3  0.61 75.7 ± 18.5 79.4 ± 16.9 0.223 
Previous ECV (0, 1, 2+), % 51/28/20 46/22/32 0.263 52/31/18 50/15/35 0.032 
Previous AF ablation (0, 1, 2+), % 82/13/5 62/27/11 0.017 85/11/4 65/24/12 0.010 
Previous class I AAD use: Y/N, % 8/92 8/92 1.000 6/94 21/79 0.008 
Previous class III AAD use: Y/N, % 46/54 59/41  0.157 42/58 71/29 0.003 
Device type: None/ILR/TD, % 55/18/27 32/3/65 <0.001 55/17/28 53/26/21 0.347 
Norepinephrine, pg/ml 646 ± 311 839 ± 519 0.030 656 ± 316 585 ± 278 0.243 
NT-proBNP, pg/ml, median (IQR) 769 (372, 1338) 1044 (528, 1983) 0.043 790 (392, 1387) 588 (263, 1147) 0.266 
AF12/HF12=AF DxT and HF DxT< 12 years. AF12/HF12/DTRI-2=AF12/HF12 and DTRI > -2 years. 
W/B/A/O=White/Black/Asian/Other. ECV=electrical cardioversion. AAD=antiarrhythmic drug. ILR=implanted loop recorder.  
TD=therapeutic device (implanted cardiac defibrillator or pacemaker). IQR=interquartile range. AF DxT=time from initial AF 
diagnosis to randomization. HF DxT=time from initial HF diagnosis to randomization. DTRI=Diagnosis to Randomization 
Index. Note: mean±standard deviations are presented unless otherwise specified. Wilcoxon Rank Sum Test for continuous 




TABLE 5. Time to First Event of AF/AFL/ACM for Subgroups by LVEF 
Cohort 
HFrEF 
LVEF < 0.50  
HFmrEF 
0.40 ≤ LVEF < 0.50 
HFlrEF 
LVEF < 0.40 
 
N (%) HR (95% CI) 
N (%)  
{% of Cohort} HR (95% CI) 
N (%) 
{% of Cohort} 
HR (95% CI) 
All Patients 267 (100) 0.92 (0.63, 1.33) 
128 (100) 
{48} 0.78 (0.45, 1.33) 
139 (100) 
{52} 1.03 (0.58, 1.83) 
AF12/HF12 230 (86) 0.68 (0.45, 1.02) 
113 (88) 
{49} 0.61 (0.34, 1.10) 
117 (84) 
{51} 0.74 (0.38, 1.44) 
AF12/HF12/DTRI-2 196 (73) 0.54 (0.33, 0.87) 
91 (71) 
{46} 0.42 (0.21, 0.86) 
107 (77) 
{54} 0.69 (0.33, 1.43) 
AF12/HF12=AF/HF DxT < 12 years; 12/12/DTRI-2=AF/HF DxT < 12 years and DTRI > -2 years.  
HFrEF=HF with reduced LVEF; HFmrEF=HF with mid-range LVEF; HFlrEF=HF with lower-range LVEF. DTRI=Diagnosis to 


















Table 6.  NT-proBNP values (pg/ml)‡ 
Parameter 
Metoprolol 
N = 123 
Bucindolol 
N = 125 
Baseline  861 (420, 1607) 777 (355, 1326) 
P value vs. Met† NA 0.378 
∆Week 4 -35 (-384, 246) -96 (-431, 70) 
P value vs. Bsl* 0.320 0.003 
P value vs. Met† NA 0.300 
∆Week 12 -50 (-610, 303) -96 (-482, 69) 
P value vs. Bsl* 0.198 0.002 
P value vs. Met† NA 0.051 
∆Week 24 -100 (-634, 117) -197 (-613, 115) 
P value vs. Bsl* 0.014 0.005 
P value vs. Met† NA 0.220 
‡Median and interquartile range presented due to non-normal 
distribution; *Wilcoxon signed rank test; †Wilcoxon rank sum 
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Note: The interim analysis methodology is not included in this plan.  That methodology can be 

















DEFINITIONS OF ANALYSIS POPULATIONS AND ENDPOINT 
FOLLOW-UP PERIODS 
The efficacy analysis will follow the intent-to-treat (ITT) principle and all patients randomized to 
study treatment will be included regardless of (1) the success of the treatment titration process 
and (2) result of electrical cardioversion (ECV) aimed at converting atrial fibrillation (AF) to 
sinus rhythm (SR).  As an additional sensitivity analysis, testing of the primary and secondary 
endpoints will be repeated on a protocol-compliant subpopulation.  Further sensitivity analyses 
specific to endpoints are described below.  The safety analyses will include all patients that 
received at least one dose of blinded study treatment.  The screened population includes any 
patient who signs informed consent for the study.  The screen failure population is a 
subpopulation of the screened population who are not randomized to study drug for any reason. 
Four follow-up periods will be defined for inclusion of each patient’s results in endpoint 
calculations: 
• Drug Titration Period: starts on the day of randomized treatment initiation and extends for six 
weeks after randomization. 
• 24-Week Follow-up Period:  starts on the day of 1) the first ECG that establishes stable SR 
(defined in Section 3.2.1), or; 2) the last ECV attempt for patients who fail to convert to 
stable SR, or; 3) the Week 0 Visit, for patients in AF who do not undergo ECV for any 
reason.  Ends on the day of the Week 24 Visit or the End of Study (EOS) Visit, if patient 
discontinues prior to Week 24 Visit. 
• Total Follow-up Period:  starts on the same day as the 24-Week Follow-up Period and 
extends until the EOS Visit. 




Screen failure reasons will be tabulated in order of frequency.  These reasons are collected on the 
eCRF DEMOG form. 
Randomization 
Randomized treatment assignment is centralized and in versions 1 and 2 of the protocol was 
stratified by: 1) HF etiology (ischemic/non-ischemic); 2) LVEF (< 0.35/ ≥ 0.35) and; 3) type of 
Medtronic device (Reveal/Non-Reveal/No Device).  In protocol version 3 a fourth strata was 
added: rhythm status at randomization: (SR vs AF).  The count of patients randomized by strata 
within each treatment group will be tabulated by site and overall.  The randomization process 
will be described in full detail. 
Baseline Characteristics 
The treatment groups will be examined for comparability with respect to demographics, 
cardiovascular history, AF risk factors, current disease state, HF and AF therapies, physical 















using descriptive statistics.  Continuous variables will be analyzed with a mean, standard error, 
standard deviation, median, minimum, maximum and n=count of results available.  Categorical 
variables will be described with n=count of results available and percentage of study population, 
with a clear explanation of the denominators provided in footnotes when necessary. 
Treatment Exposure and Compliance 
The treatment groups will be examined for comparability with respect to the outcome of the 
titration period (broken down by pre-study beta blocker usage), the attainment of target dose and 
the days of double blind treatment by dose level and overall.  Elapsed days and days of treatment 
exposure during the four follow-up periods will also be described by treatment group. 
Compliance since the previous visit is reported by the sites on the VISREC eCRF form.  Overall 
compliance rates for the 24-Week Follow-up Period and the Total Study Period will be 
calculated for each patient and compared between the two treatment groups with descriptive 
statistics.  Note that if a patient discontinues study treatment, compliance is calculated through 
the date of discontinuation. 
Concomitant Medications 
Patients must be receiving optimal anticoagulation therapy for stroke prevention.  A tabulation 
of anticoagulant drug usage by treatment group will be generated.  For warfarin users, INR is 
collected on the LAB eCRF as the following ranges: < 1, ≥  and < 2, ≥ 2 and < 3, ≥ 3 and < 
4, ≥ 4.  A tabulation of these reported ranges by treatment group will be generated for each of 
the study visits in which reporting is required. 
Reported usage of all concomitant medications during the study will be standardized with 
preferred name and Anatomical Therapeutic Classification (ATC) using the WHODrug 
dictionary for tabulation by treatment group. 
Metrics for Key Study Procedures 
Metrics for the following study procedures and medical interventions will be presented with 
descriptive statistics by randomized treatment group: 
• The cardiac rhythm status of every patient at both the Randomization Visit and at the 
start of the 24-Week Follow-up Period will be tabulated as follows. 
– Patients in Stable SR at Week 0 who did not require ECV 
 Pts in SR at Randomization 
 Pts in AF at Randomization 
–  Patients in Stable SR at Week 0 who did require ECV 
 Pts in SR at Randomization 
 Pts in AF at Randomization 
–  Patients in AF/AFL at Week 0 















 Pts in AF at Randomization 
–  Death/Loss to Follow-up (LTF) prior to Week 0 
 Pts in SR at Randomization 
 Pts in AF at Randomization 
• Elapsed days on treatment prior to ECV. 
• Outcome of ECV. 
• Compliance with procedures for collection of transtelephonic monitoring (TTM) results, 
and 
• Compliance with procedures for collection of Medtronic device results. 
Final Study Disposition 
The disposition of patients screened and randomized into the study will be tabulated by treatment 
group and displayed with a flow diagram.  This will include the counts of screens, screen 
failures, re-screens, randomizations, completion of the Week 24 Visit, reasons for permanent 
discontinuation of study treatment and reasons for discontinuation of study follow-up (broken 
down by pre/post Week 24 Visit).  Note that all patients classified as completing the Week 24 
Visit will have all components of the primary and secondary endpoints ascertained through the 
entire 24-Week Follow-up Period. 
Protocol Deviations 
ARCA Clinical Operations maintains an Excel spreadsheet of protocol deviations reported 
during the study.  Each protocol deviation is classified as being Major or Minor, based on its 
potential impact on clinical results per ARCA SOP CLIN-005.  Tabulations and listings of the 
reported protocol deviations will be provided for both treatment groups. 
EFFICACY ANALYSIS 
General Methodology 
Time-to-Event Analysis Methodology 
Time-to-event is calculated as the date of the event minus the date of initiation of efficacy 
follow-up, with 1 added in order to include both the start date and end date of the interval. 
For all endpoints, follow-up will be censored when a patient receives a cardiac transplant, is 
declared to be permanently lost to follow-up or withdraws consent.  The follow-up periods and 
specific censoring rules are identified in the endpoint descriptions. 
These analyses will be a two-tailed comparison of bucindolol and metoprolol, using the log rank 
statistic with the exact variance calculation stratified by the randomized treatment assignment 
strata: 1) HF etiology (ischemic/non-ischemic); 2) LVEF (< 0.35/ ≥ 0.35); 3) type of Medtronic 
device (Reveal/Non-Reveal/No Device); and 4) rhythm status at randomization: (SR vs AF).  
Note that patients enrolled under versions 1 and 2 of the protocol were not stratified by rhythm 
status however their rhythm status is known due to inclusion criteria (all were in AF).  The 















variables specified in the STRATA statement and the TEST statement used to specify the 
treatment group comparator and any covariates being examined.  Cox’s proportional hazards 
model will be used to calculate estimated hazard ratios and 95% confidence intervals.  The 
calculations will be performed with the SAS PHREG procedure, with the stratification variables 
specified in the STRATA statement and the treatment group comparator and any covariates 
being examined specified in the MODEL statement.  For the primary endpoint, the 
appropriateness of assuming proportional hazards will be explored by the graphing of log (-
log(survival function)) over follow-up for each treatment group. 
Where appropriate, Kaplan-Meier survival curves for bucindolol versus metoprolol will be 
generated to provide a graphical comparison of the two treatment groups. 
Follow-up for the time-to-event endpoints will generally end either at the Week 24 Visit or the 
EOS Visit for the Total Follow-up Period or Total Study Period endpoints.  If the Week 24 Visit 
falls later than day 180, follow-up will be censored on day 180. 
Components of Combined Endpoints 
This report will contain many endpoints that involve the time to the first occurrence of multiple 
events, such as AF/AFL onset, mortality or hospitalization.  For these endpoints, the count of 
first events provided by each component will be tabulated.  In addition, each component of the 
combined endpoints will be analyzed separately with a time-to-first-event analysis following the 
same methodologies used for the combined statistic. 
Adjudication 
A Clinical Events Classification (CEC) group will adjudicate the primary endpoint, first 
symptomatic AF/AFL event or death during the 24-Week Follow-up Period.  As part of the 
adjudication process for the primary endpoint, the CEC will also evaluate the secondary endpoint 
of first AF/AFL event (i.e., symptomatic or asymptomatic).  Specifically, the ECGs for the first 
report of AF/AFL will be reviewed and adjudicated for the presence of AF/AFL regardless of the 
symptom status.  If the first protocol-defined AF/AFL event is not considered a symptomatic 
AF/AFL event, the triggering process will continue for that patient until the first symptomatic 
AF/AFL event is identified for the primary endpoint.  The CEC over-read of ECG tracings will 
be used in the calculation of other pertinent study endpoints (such as non-symptomatic AF/AFL 
within the 24-Week Follow-up Period).  More details can be found in the CEC Charter. 
Core Lab and Transtelephonic Monitoring 
In the original study protocol, an Electrophysiology Core Lab (Agility Centralized Research 
Services) provided a centralized ECG interpretation of the individual ECGs performed at the 
clinic site and the transtelephonic monitors (TTM) worn by the patients, both during the 24-
Week Follow-up Period.  In version 4 of the protocol, the collection of these two sources of data 
was discontinued.  The CEC adjudication process was not in production mode at that time point, 
so it was decided the CEC would perform their own interpretation (over-reads) of the site ECG 
tracings and not use any of the Core Lab interpretations.  Further, the CEC adjudication would 
















Many of the efficacy endpoints involve hospitalization.  Only non-voluntary, overnight hospital 
admissions will be included in these endpoints; emergency room visits will not be included.  
Patients in this study will often have scheduled hospital admissions for treatment of their AF 
and/or HF.  Examples include ablation procedures, Tikosyn induction, placement/replacement of 
implanted devices, and IV drug treatment.  These will not be included in the endpoints.  The 
eCRF specifically collects the investigator’s assessment of hospitalization causation, which 
includes assessments of non-CV, CV and HF hospitalizations.  In addition to the investigator 
assessment of causation, the data will be reviewed by the Sponsor via a blinded listing review 
prior to database lock to confirm which hospitalizations are considered voluntary, overnight 
admissions. 
Data Collection Cut-off at End of Study 
The protocol states the study will end with approximately 620 randomized patients and accrual 
of at least 330 primary endpoint events, presuming the sample size and target event counts are 
not altered due to the Phase 3 interim analysis (see DSMB Charter).  At this point, any patients 
still participating in the 24-Week Follow-up Period will remain on blinded study treatment until 
they complete the Week 24 Visit.  Those patients in the Extension Period will be called in for an 
EOS Visit. 
Missing Data Due to Withdrawal or Loss to Follow-up 
The rate of withdrawal or loss to follow-up prior to the Week 24 Visit is expected to be low.  If a 
withdrawal or loss to follow-up occurs prior to the Week 24 Visit, all time-to-event endpoints 
will be censored as of the last completed visit.  Note that patients that withdraw from the study 
will be requested to consent to have their vital status checked via phone calls.  If deaths are 
detected by this procedure the date of death will be incorporated into the efficacy and safety 
datasets and analyses. 
P-value Adjustment for Interim Analysis 
The goals and operational details for the interim efficacy analysis and ongoing safety monitoring 
can be found in the DSMB Charter and the DSMB SAP. 
At the end of Phase 3, the alpha level for the primary endpoint will be reduced to 0.04989 to 
adjust for the Phase 2B (α = 0.00001) and Phase 3 (α = 0.0001) interim analyses. 
Efficacy Endpoints 
Primary Efficacy Endpoint 
The primary endpoint is elapsed time-to-first-event of symptomatic AF/AFL or all-cause 
mortality (ACM) during the 24-Week Follow-up Period.  This is a time-to-event endpoint 
censored at the end of the 24-Week Follow-up Period.  The identification of first event of 
symptomatic AF/AFL or death is provided by the CEC.  The CEC does not distinguish between 
the presence of AF or AFL so a component analysis will not be possible. 
The following definitions apply to this endpoint: 
• Stable SR on study drug is defined as any of the following: 















– SR confirmed ≥ 1 hour after spontaneous conversion from AF/AFL. 
– SR confirmed ≥ 1 hour at the Week 0 Visit for patients randomized in SR. 
• An AF/AFL event is defined as AF or AFL observed on two consecutive measures 
separated by at least 10 minutes as assessed by ECG/TTM. 
• A symptomatic AF/AFL event is defined as an AF/AFL event that is associated with a 
clinically relevant change in patient-reported symptoms, as determined by the CEC 
examination of blinded data. 
The CEC charter and associated documents describe the “triggers” that are established to identify 
events for their consideration and the data sources to be used in their adjudication proceedings.  
The charter also describes their approach for identifying an AF event as symptomatic and for 
identifying the onset date and time of the event since that is needed for this time-to-event 
endpoint.  Note that version 3 of the protocol involved a comprehensive change to the symptoms 
collected, with 6 of the original 8 symptoms having their descriptions modified and 2 new 
symptoms being added.  Also the symptom characteristics were clarified with addition of a 
‘frequency’ field to the collection form.  All of these changes were made to give the CEC more 
specific information to support their identifying symptoms that were new or worsened in 
association with AF onset.  Since these changes were implemented after only 12 patients were 
randomized (2% of the planned 620) and the identification of overall symptom onset/worsening 
is an adjudicated decision, no modification of analysis methodology is planned. 
AF/AFL will be assessed at scheduled and unscheduled clinic visits via 12-lead ECG.  Patients 
will be queried at the time of each ECG assessment to determine if they have experienced any 
change in symptoms that could be potentially related to AF. 
The vast majority of patients will either be in SR or successfully convert from AF to SR after one 
or two ECV procedures around three weeks after they begin randomized treatment.  However, 
there are several scenarios that depart from this norm and the methodology for establishing the 
start of efficacy follow-up and censoring for the primary endpoint is described below: 
1. Spontaneous conversion to stable SR prior to the planned cardioversion.  For these 
patients, the day of the first ECG assessment that meets the definition of stable SR, as 
defined above, will be designated as Day 1 of the 24-Week Follow-up Period. 
2. Failure to attain stable SR because the ECV procedure was not performed due to drop out 
or any reason other than those described below.  These patients will be included in the 
analysis as censored on Day 1 of the 24-Week Follow-up Period. 
3. Failure to attain stable SR, either spontaneously or following ECV.  These patients will 
be included in the endpoint calculation as experiencing the event on Day 1 of the 24-
Week Follow-up Period. 
4. Deaths occurring after randomization and prior to conversion to stable SR will be 
counted as events on Day 1 of the 24-Week Follow-up Period. 
5. Patients with AF/AFL stopped at the Week 0 visit by any means other than ECV will be 
censored on Day 1 of the 24-Week Follow-up Period.  An example is the performance of 















The primary endpoint analysis will also be performed within the following prospectively 
identified subgroups based on pathophysiological or clinical importance: 
1) Started the 24-Week Follow-up Period in SR vs AF 
2) LVEF strata at randomization:  ≤0.35 vs. >35 
3) Gender 
4) Ischemic etiology vs. nonischemic 
5) Age above/below median 
6) Duration of AF diagnosis above and below median. 
7) Baseline norepinephrine above and below median 
8) Baseline NT-proBNP 
9) α2C AR polymorphisms (i.e., Del carriers vs. α2C wild type homozygotes). 
In exploratory analyses, the following covariates will be included as potentially relevant 
explanatory variables in the Cox regression models: 
1. Initial study treatment dose level.  




6. Baseline serum creatinine. 
7. Baseline norepinephrine level. 
8. Baseline heart rate. 
9. Baseline systolic blood pressure. 
10. History of diabetes. 
11. Duration of AF diagnosis. 
12. Previous amiodarone use (both historical and stopped just prior to randomization). 
13. Ablation procedure prior to study. 
14.  Therapeutic device type: CRT, ICD, single ventricular lead pacemaker. 
15. For the subset of patients in AF at baseline, type of rhythm abnormality: (paroxysmal AF 
or persistent AF). 
16. For the subset of patients in SR at baseline: the time since last attaining SR, the type of 
previous rhythm abnormality, and the intervention that ended the previous AF episode. 
17. Elapsed days of treatment from randomization date to start of the 24-Week Follow-up 
Period. 
18. CYP2D6 metabolizer status. 
19. α2C AR polymorphisms (i.e., Del carriers vs. α2C wild type homozygotes). 
20. Country in which clinic site is located. 
21. Other clinically significant AF risk factors. 
Additional exploratory analyses will include the following: 
• A qualitative analysis of the symptoms associated with the primary endpoint events.  The 
symptoms will be classified as arrhythmia-related (palpitations or 
lightheadedness/dizziness) HF-related (fatigue or tiredness, weakness or problems 















• For patients with primary endpoint events of symptomatic AF/AFL, how many had prior 
events of asymptomatic AF/AF that progressed into symptomatic. 
The following sensitivity analyses will be performed: 
• A subpopulation analysis including only those patients beginning the 24-Week Follow-up 
Period in SR. 
• In the per-protocol analysis, endpoint events and deaths that occur more than 30 days 
after permanent discontinuation of study treatment are omitted. 
• All Week 24 Visits included (ie - no exclusion of events observed at Week 24 Visits after 
day 180). 
• Patients that have not previously reverted to AF/AFL that withdraw or are lost to follow-
up prior to the Week 24 Visit, will be assigned an AF/AFL event at the first missed clinic 
visit or scheduled TTM. 
• Patients that withdraw or are lost to follow-up prior to the Week 24 Visit are omitted 
from the analysis. 
Secondary Efficacy Endpoints 
The following endpoints will be tested for superiority of bucindolol benefit relative to metoprolol 
by fixed sequence provided that bucindolol is found to be significantly superior in the primary 
endpoint.  The time-to-event endpoint methodology described in Sections 3.1.1 and 3.2.1 for 
events involving AF/AFL recurrence will be used unless otherwise noted: 
• Time-to-first-event of AF/AFL (i.e., symptomatic or asymptomatic) or ACM during the 
24-Week Follow-up Period. 
Supportive Analyses: 
Events accrued during the Total Follow-up Period. 
For patients with events based on symptomatic AFL, the rate of patients subsequently 
progressing to AF.  Also for these patients, the elapsed time from symptomatic 
AFL to AF. 
Data Source: 
ECG (over-read by CEC for first 24 weeks) 
TTM (first 24 weeks only) 
• Proportion of patients with VT, VF, or symptomatic supraventricular tachycardia (SVT) 
during the 24-Week Follow-up Period. Includes VF and symptomatic SVT events of any 
duration, VT events ≥ 15 seconds, and VT events that result in appropriate firing of an 
ICD.  It will be tested with a Cochran-Mantel-Haenszel statistic to control for the four 
stratification variables. 
Supportive Analyses: 
















The CVEVENT eCRF form is the source of all components of these compound 
endpoints. 
• Total all-cause hospitalization days per patient during the Total Study Period.  The count 
of hospitalization days will be normalized for the total number of days of follow-up prior 
to testing with the Wilcoxon Rank Sum statistic. 
Supportive Analyses: 
Number of heart failure hospitalization days per patient. 
All-cause hospitalization days through first recurrence of AF/AFL versus days after 
recurrence, normalized for days of follow-up within each period.  The comparison 
will take place within treatment group and across treatment. 
All-cause hospitalization days for patients with ventricular rate control (VRR) control 
compared to those without VRR control.  The comparison will take place within 
treatment group and across treatment. 
Data Source: 
The HOSP eCRF form provides the number of hospitalization days and the reason for 
hospitalization. 
The ECG and AE eCRF will be used to identify the patients in AF with VRR control 
at the end of the study. 
• Time-to-first-event of AF/AFL (i.e., symptomatic or asymptomatic), HF hospitalization 
(as assessed by the Investigator), or ACM during the Total Follow-up Period.  As in the 
primary endpoint, any incidence of ACM prior to start of the 24-Week Follow-up Period 
will be analyzed as an event on Day 1.  Hospitalization prior to Week 0 are not included, 
but those are included in the safety analyses. 
Supportive Analyses: 
– Events accrued during the 24-Week Follow-up Period. 
– Combinations of each component ((i.e., AF/AFL+ACM, AF/AFL+HFH, 
HFH+ACM). 
Data Source: 
– ECG (over-read by CEC for first 24 weeks), HOSP and DEATH eCRF forms. 
– TTM (first 24 weeks only). 
• Proportion of patients with adequate ventricular rate control (VRR) in the setting of 
AF/AFL.  Adequate VRR in setting of AF/AFL is defined as follows: 1) the presence of 
AF or AFL; 2) a VRR between 40 and 80 beats per minute (bpm) at rest; and 3) the 
absence of symptoms associated with bradycardia.  Thus this is a subset analysis only 
involving patients with AF/AFL recurrence.  The endpoint is evaluated for the last tracing 















ablation, ECV, initiation of anti-arrhythmic drugs).  Will be tested with a Cochran-
Mantel-Haenszel statistic to control for the four stratification variables. 
Supportive Analyses: 
– Evaluated for the last tracing demonstrating AF/AFL when the patient is still on 
study treatment during the 24-Week Follow-up Period. 
Data Source: 
– ECG and AE eCRF form (for symptomatic bradycardia). 
Tertiary Efficacy Endpoints 
The following endpoints will be tested for superiority of bucindolol benefit relative to 
metoprolol. The time-to-event endpoint methodology described in Section 3.1.1 and 3.2.1 for 
events involving AF/AFL recurrence will be used unless otherwise noted: 
• Time-to-first-event of VT/VF or ACM during the Total Follow-up Period.  Includes VF 
events of any duration, VT events of ≥ 15 seconds, and VT events that result in 
appropriate firing of an ICD. 
Supportive Analyses:  
– Events accrued during the 24-Week Follow-up Period. 
Data Source: 
– CVEVENT and DEATH eCRF forms. 
• Time-to-first-event of AF/AFL (i.e., symptomatic or asymptomatic), CV-related 
hospitalization (as assessed by the Investigator), or ACM during the Total Study Follow-
up Period. 
Supportive Analyses: 
– Events accrued during the 24-Week Follow-up Period. 
– Combinations of each component (i.e., AF/AFL+ACM, AF/AFL+CVH, 
CVH+ACM). 
Data Source: 
– ECG (over-read by CEC during the 24-Week Follow-up Period), HOSP and 
DEATH eCRF forms. 
– TTM (24-Week Follow-up Period). 
• Proportion of patients with stroke or systemic embolism during the Total Follow-up 
Period.  Stroke is defined as a focal neurologic deficit from a non-traumatic ischemic, 
hemorrhagic, or uncertain cause lasting at least 24 hours (as assessed by the Investigator).  

















– CVEVENT eCRF form. 
• Proportion of patients randomized with AF/AFL who convert to stable SR (spontaneous 
or post-ECV) and enter the 24-Week Follow-up Period.  Tested with a Cochran-Mantel-
Haenszel statistic to control for the four stratification variables. 
Supportive Analyses: 
Subset of patients with spontaneous conversion. 
Data Source: 
FUSTART eCRF form. 
• Total number of ECV procedures per patient during the Total Study Period.  This count 
will be normalized for the total number of days of follow-up prior to testing with the 
Wilcoxon Rank Sum statistic. 
Data Source: 
ECV eCRF form. 
• Proportion of patients at Week 24 Visit who are receiving study drug and have not had an 
AF/AFL event.  Tested with a Cochran-Mantel-Haenszel statistic to control for the four 
stratification variables. 
Data Source: 
ECG (over-read by CEC), DRUGLOG and EOT eCRF forms. 
TTM (24-Week Follow-up Period). 
• Change in NT-proBNP, assessed relative to baseline (Randomization Visit).  Change 
from baseline will be tested for greater reduction in the bucindolol treatment group with 
the Wilcoxon Rank Sum test because of the expected lack of normality of this measure. 
Data source: 
LabCorp vendor dataset. 
• Change in norepinephrine, assessed relative to baseline (Randomization Visit).  Change 
from baseline will be tested for greater reduction in the bucindolol treatment group with 
the Wilcoxon Rank Sum test because of the expected lack of normality of this measure. 
Data source:  
LabCorp vendor dataset. 
• The EQ-5D questionnaire has 5 dimensions (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) and each is self-rated by the patient as no 
problems, some problems, or severe problems.  The results for each dimension will be 
analyzed individually at both time points.  The change from randomization to each visit 
will be categorized as improved or no change/worsened and the proportions of these 















treatment group will be tested for superior response using a Cochran-Mantel-Haenszel 
statistic to control for the four stratification variables. 
Data source: 
EQ-5D eCRF form. 
• Pharmacoeconomic modeling of healthcare utilization.  Details of this analysis will be 
prespecified in a separate analysis plan. 
SAFETY ANALYSIS 
The following four periods are established for analysis of safety endpoints: 
• 24-Week On-Drug Period:  starts at day of randomization and extends to latest visit 
attended through Week 24 Visit.  For patients that discontinue treatment early, data 
collected through 30 days after the final dose of study treatment are included. 
• 24-Week On-Study Period:  starts at day of randomization and extends to latest visit 
attended through Week 24 Visit.  For patients that discontinue the study prior to Week 
24, data collected through 30 days after the final study visit are included.  Study 
treatment status is not considered for data inclusion. 
• Total Study On-Drug Period:  starts at day of randomization and extends through 30 days 
after the final dose of study treatment. 
• Total Study On-Study Period:  starts at day of randomization and extends through 30 
days after final clinic visit attended.  Study treatment status is not considered for data 
inclusion. 
Analysis of SAEs will be performed for all four timeframes.  For the other safety endpoints, the 
24-Week On-Study and Total Study On-Study Periods will be used.  If treatment group 
imbalances are observed for an endpoint, it will be further analyzed with the other data inclusion 
timeframes. 
The results for the following safety endpoints will be compared with descriptive statistics 
between the treatment groups for all patients receiving study treatment.  Results collected from 
first dose of study drug to 30 days after the last dose for each patient will be included in the 
assessments of safety.  Results specific to scheduled visits will be included in the by-visit 
analyses if they were collected within a ± 7-day window for the prescribed visit study day. 
• Incidence of ACM during the Total Study Period. 
Supportive Analyses: 
The association of VRR control with mortality will be examined using the final heart 
rate measurement available for each patient (comparisons will be within the 
treatment groups). 
Data Source: 















• Incidence of ACM, CV-related hospitalization (as assessed by the Investigator), or 
withdrawal of study drug due to an AE during the Drug Titration Period. 
Data source: 
DEATH, HOSP, EOS and AE eCRF forms. 
• Incidence of symptomatic heart block during the Total Study Period.  Symptomatic Heart 
Block is defined as the first of any of the following:  1) 3rd degree heart block (complete 
heart block); 2) any 2nd degree heart block with the presence of symptoms attributable 
to, and temporally correlated with the occurrence of heart block which include any of the 
following: Near-fainting or fainting (syncope) / Dizziness; Weakness or Fatigue; 
Shortness of breath; Chest pain; or 3) 2nd or 3rd degree heart block requiring 
implantation of a permanent pacemaker (with or without defibrillator). 
Data source: 
CVEVENT and AE eCRF forms. 
• Overall incidence and severity of treatment-emergent AEs/SAEs over time during the 
Total Study Period.  Also events associated with device implantation.  The events will 
have standardized MedDRA preferred terms and System Organ Classes assigned to them 
for tabulation. 
Supportive analyses: 
Incidence of AEs leading to reduction, interruption or permanent discontinuation of 
study treatment. 
Incidence of AEs associated with device implantation. 
Incidence of AEs by CYP2D6 metabolizer status. 
Incidence of AEs by α2C AR polymorphisms. 
Data source: 
AE eCRF form. 
• Incidence of neoplasm-related AEs during the Total Study Period.  The AEs of special 
interest will be tabulated according to the following characteristics. 
Development of treatment-emergent neoplastic conditions. 
Progression or worsening of pre-study neoplastic conditions. 
Progression or worsening of treatment-emergent neoplastic conditions. 
Data source:  
– AE, NEOPLHX and NEOPLAS eCRF forms. 
• Clinical Chemistry and Hematology.  
Visit collection: screen, start of follow-up Week 0 (protocol versions 1 and 2), Week 















every 24 weeks during extension, end of treatment and end of study.  Screen 
results will serve as the pre-treatment baseline. 
Change from baseline to each planned study visit of collection will be calculated and 
analyzed with descriptive statistics. 
The numbers and percentages of patients with values exceeding the bounds of normal 
ranges will be tabulated for scheduled visits. 
The numbers and percentages of patients with values exceeding the panic bounds 
each visit. 
Data source: 
LabCorp vendor-supplied dataset. 
• ECG quantitative parameters. 
Measured at every visit.  Randomization Visit measurement prior to first dose will 
serve as the baseline.  Will be analyzed at Week 0, 4, 12 and 24 visits as well as 
end of treatment and end of study. 
Change from baseline to each analysis visit will be calculated and analyzed with 
descriptive statistics. 
The numbers and percentages of patients with QTc increase from baseline exceeding 
60 ms at any time point during the study. 
Data source:  
– ECG eCRF form. 
• Vital signs and weight (data source: VITALS eCRF form). 
Measured at every in-clinic visit.  Randomization Visit measurement prior to first 
dose will serve as the baseline.  Will be analyzed at Week 0, 4, 12 and 24 visits as 
well as end of treatment and end of study. 
Change from baseline to each analysis visit will be calculated and analyzed with 
descriptive statistics. 
Data source: 
VITALS eCRF form. 
• Proportion of patients attaining target study drug dose during the Drug Titration Period.  
Will be calculated for all patients, those receiving β-blocker therapy prior to 
randomization and those not previously receiving β-blocker therapy. 
Data Sources: 
VISREC and DRUGLOG eCRF forms. 
MEASUREMENTS OF INTEREST AND SUBSTUDIES 















In this optional substudy, AFB, defined as the amount of time per day that a patient is in 
AF/AFL, is measured by implanted Medtronic devices, including cardiac monitors, 
pacemakers, cardioverter-defibrillators, and cardiac resynchronization therapy.  These 
devices also measure VRR during periods of AF.  Approximately 50% of the study 
participants are expected to participate in the AFB substudy. 
The distribution of device types will be presented by treatment group, by patient baseline 
characteristics, by disease severity, by treatment exposure prior to device implantation 
and elapsed days to start of the 24-Week Follow-up Period.  AFB will be presented as 
hours/day in graphical displays for each patient with the dates of randomization and 
initial ECV and other interventions annotated. 
The treatment efficacy endpoint will be the time to first device-detected event or ACM, 
with an event defined as at least 6 hours of AFB in a single day.  This endpoint will be 
analyzed through the Week 24 Visit with the same methodology used for the study 
primary endpoint. Patients with no AFB data available after the start of the 24-Week 
Follow-up Period will be excluded.  Patients with an implanted therapeutic device that 
produces paced rhythm which confounds the measurement of AFB will also be excluded. 
• Supportive Analyses: 
Time to device detected AF/AFL event during the Total Follow-up Period. 
The proportion of patients with VRR on the last day demonstrating AF/AFL during the 
24-Week Follow-up Period.  Will be tested using a Cochran-Mantel-Haenszel statistic to 
control for the four stratification variables. 
The percent of follow-up days in AFB, calculated as the number of days with AFB of at 
least six hours divided by the total number of days in the 24-Week Follow-up Period.  
Statistical testing will be performed with the Wilcoxon Rank Sum Statistic.  A sensitivity 
analysis will be performed on the subset of patients beginning the 24-Week Follow-up 
Period in SR. 
• Data Sources: 
Medtronic vendor-supplied dataset. 
• DNA Bank, with collection at time of screening, for patients who agree to participate in 
the substudy.  No analysis of these data have been pre-planned. 
• Sparse sampling of bucindolol hydrochloride plasma concentrations for population 
pharmacokinetic analysis.  The analysis plan for the substudy will be prepared separately 
















GENETIC-AF Clinical Trial  
Phase 2B Statistical Analysis Plan Amendment 
RATIONALE FOR PHASE 2B STATISTICAL ANALYSIS PLAN  
On the pre-specified first interim analysis of the GENETIC-AF trial conducted on August 7, 
2017, based on application of pre-defined Bayesian predictive probability of success (PPoS) 
modeling of the “modified primary endpoint” data, the GENETIC-AF Data and Safety 
Monitoring Board (DSMB) recommended completing the trial in Phase 2B rather than 
immediately stopping for futility or “seamlessly” transitioning to Phase 3. Shortly thereafter, the 
Sponsor (ARCA biopharma) informed the trial investigators of the DSMB decision and 
instructed sites to complete follow-up of all randomized patients by December 31, 2017. This 
implies that 267 patients will constitute the final Phase 2B population, with nearly all of them 
having completed the planned 24 weeks of follow-up or having reached the Phase 2B modified 
primary endpoint (hereafter referred to as the Phase 2B primary endpoint) of time to 
symptomatic or asymptomatic atrial fibrillation/atrial flutter (AF/AFL) or all-cause mortality 
(ACM). 
The DSMB Phase 2B interim analysis, conducted and reported to the Sponsor on August 7, 2017 
was based on 103 AF/AFL/ACM events from 215 patients randomized through June 19, 2017 
including 162 who had attained full follow-up or experienced the Phase 2B primary endpoint. In 
contrast, the completed Phase 2B dataset on 267 patients will likely include approximately 50% 
more Phase 2B primary endpoint events. Currently the patients are attending final study visits 
and all data are being subjected to full monitoring QA during close-out of each site. ARCA 
expects to receive the final data and treatment assignments in February of 2018.  
The GENETIC-AF Statistical Analysis Plan (SAP)1, which focused primarily on analyses 
pertinent to the Phase 3 population, was completed on March 15, 2017 and submitted to FDA on 
March 30, 2017. In the Phase 3 SAP, the primary efficacy endpoint is time to symptomatic 
AF/AFL or ACM, which was powered based on an expectation of 330 events from a total of 
approximately 620 patients. As this study is now stopping at Phase 2B, ARCA estimates that the 
total number of events will be less than half of what was planned for the full Phase 3 study. As 
such, the prespecified analysis described in the SAP for the Phase 3 primary endpoint is not 
expected to provide adequate guidance to the Sponsor regarding the utility of conducting a 
reasonably sized Phase 3 trial based on a time to AF/AFL/ACM primary endpoint. 
The DSMB charter2 was approved on October 13, 2015 and submitted to FDA on October 16, 
2015. In the charter, the DSMB acknowledges that a traditional time-to-first AF/AFL/ACM 
event analysis would have very low statistical power for a population of 200-250 patients; 
therefore, the DSMB charter and an accompanying white paper3 outlined a Bayesian 
methodology for the interim analysis that would be more informative for the Phase 2B 
population.  More specifically, the DSMB charter identified time to first event of symptomatic or 
asymptomatic AF/AFL or ACM as the primary efficacy endpoint for the Phase 2B interim 
analysis, since this more inclusive endpoint was expected to have significantly more events than 
the Phase 3 primary endpoint (i.e., symptomatic AF/AFL or ACM). ARCA’s ongoing review of 
blinded data supports this conclusion, with approximately 75% of first AF/AFL events being 















Therefore, ARCA plans to conduct the primary efficacy analysis of this Phase 2B study in a 
similar manner, following the Bayesian methodology that was prespecified in the DSMB charter 
for the Phase 2B interim analysis. As described below, these analyses will model the Phase 2B 
data to generate Bayesian predictive probability of success (PPoS) values for a discrete Phase 3 
trial with 620 randomized patients who have accrued 330 events (i.e., ymptomatic or 
asymptomatic AF/AFL or ACM). Additional Bayesian modeling will also be performed for Phase 3 
planning purposes but these analyses will be secondary to the Phase 2B primary efficacy analysis 
described above. ARCA will also perform all analyses described in the GENETIC-AF SAP, 
recognizing that most of these endpoints (e.g., symptomatic AF/AFL, hospitalizations, mortality) 
will be significantly under powered and primarily hypothesis-generating in nature. 
DESCRIPTION OF PHASE 2B STATISTICAL ANALYSES 
As described in the DSMB Charter2, the of time to first event of AF/AFL or ACM endpoint will 
be subjected to Bayesian modeling for derivation of PPoS estimates by Berry Consultants, 
Austin TX (Dr. Ben Saville, Project Lead). The PPoS bands and boundaries, identical to those 
described in the first interim analysis, are given in Figure 1 and will be used to inform/guide the 
Sponsor. The primary efficacy analysis will be based on Bayesian modeling of the Phase 2B data 
assuming a discrete Phase 3 population of 620 patients with 330 events (i.e., symptomatic or 
asymptomatic AF/AFL or ACM). 
A secondary analysis will also be performed based on Bayesian modeling of the Phase 2B data 
assuming a discrete Phase 3 population of 820 patients with 440 events (i.e., symptomatic or 
asymptomatic AF/AFL or ACM). This secondary analysis reflects what ARCA believes is the 
approximate upper bounds of clinical feasibility for a Phase 3 trial, and was the final sample size 
planned for the current study if the second (Phase 3) interim analysis described in the DSMB 
Charter2 indicated that the data was in the “promising zone”4. 
As described in Section 3.2.1 of the GENETIC-AF SAP1, sensitivity analyses will be performed 
on both the primary and secondary models described above for the subset of patients who began 
the 24-week Follow-up Period in sinus rhythm. Additional exploratory analyses may also be 
performed with other sample sizes and event rates, as necessary. 
 
Figure 1. Predictive Probability of Success (PPoS) bands and boundary designations 
for Bayesian modeling of the GENETIC-AF Phase 2B primary endpoint of time to 















All analyses described above will also be repeated for the symptomatic AF/AFL or ACM 
endpoint; however, since there are significantly fewer events for this endpoint these analyses are 
considered exploratory and the PPoS boundaries in Figure 1 do not directly apply.  
To determine if modification of inclusion/exclusion criteria could improve the design of a future 
Phase 3 trial, exploratory Bayesian analyses will be conducted following the primary (i.e., 620 
patients/330 events) and secondary (i.e., 820 patients/440 events) models described above to 
explore treatment effects in various subgroups.  
1 Subgroups of interests are prespecified in Section 3.2.1 of the GENETIC-AF SAP1. For the 
Phase 2B analysis, the following subgroups have been prioritized in order of importance based 
on pathophysiological and/or clinical relevance: 
1) Randomized in sinus rhythm versus AF/AFL 
2) LVEF at randomization: ≤ 0.35 versus > 0.35 
3) History of persistent AF versus paroxysmal AF 
4) Geographic region (USA, Canada, or Europe) 
Due to well-known issues associated with inflated false positive rates with subgroup analyses, 
these analyses will focus on estimation rather than hypothesis testing, and will incorporate 
Bayesian hierarchical methods to shrink estimated treatment effects in subgroups toward the 
respective estimate in the overall study population.  The GENETIC-AF Steering Committee, 
which consists of AF and heart failure experts will review the subgroup analyses and determine 
whether there exists sufficient biologic or clinical plausibility to support further development in 
any of the subgroups.  
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Classification of Heart Failure by LVEF 
The definition of heart failure with reduced LV ejection fraction based on a lower limit of 
normal of 0.50 (1, 2) was used to define HFrEF (LVEF < 0.50 and a history of HF). HFrEF 
patients were subdivided into HFmrEF (HF with mid-range LVEF) according to Ponikowski et 
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Modeling of Variables and Selection of Optimal Boundaries for Therapeutic Phenotypes 
In this exploratory Phase 2 trial with limited sample size and statistical power, we employed 
precision therapeutic phenotyping to identify HF populations who respond differentially to two 
beta-blockers based on genetic targeting. This approach circumvents potential issues associated 
with conventional subset analyses by evaluating monotonicity and consistency of trends across 
the full continuum of candidate variables. The benefit of deriving these therapeutic phenotype 
characteristics from continuous variables is that the classifiers are readily conducive to numerical 
calibration. With discrete and/or categorical classifiers, a hypothetical predictor variable is either 
correct or not, with limited or no gradation possible as a hedge against spuriousness. For the 
calibration of the continuous variable DxT and DTRI, one could select more restrictive criteria 
such as DxT10/DTRI-1 (i.e., < 10 years of AF and HF with AF not preceding HF by more than 1 
year), which yields a similar treatment effect estimate (HR = 0.51; 95% CI: 0.30, 0.85) compared 
to DxT12/DTRI-2 (HR = 0.54; 95% CI: 0.33, 0.87); whereas, more inclusive criteria such as 
DxT15/DTRI-3 results in only a slight loss of signal (HR = 0.63; 95% CI: 0.40, 0.98). We 
propose that increasing the permissible limits of variation (i.e., tolerance) for the phenotype 


















AF Symptoms Questionnaire (AFSQ) 
1. Since your last clinic visit, have you experienced any of the following: 
a) Heart palpitations (pounding, racing or irregular heart beat)? [Yes/No] 
b) Shortness of breath?  [Yes/No] 
c) Chest pain or pressure?  [Yes/No] 
d) Fatigue or tiredness?  [Yes/No] 
e) Weakness or problems exercising?  [Yes/No] 
f) Lightheadedness, dizziness or fainting?  [Yes/No] 
g) Confusion/trouble concentrating?  [Yes/No] 
h) Sweating unrelated to physical activity?  [Yes/No] 
i) Weight gain greater than 2 pounds?  [Yes/No] 
j) Swelling of both legs and/or feet?  [Yes/No] 
 
2. Which symptom do you consider the predominant or worst symptom?   
[choose only one from above, or ‘NA’ if no symptom experienced] 
 
3. For questions 1a-j, if “yes” collect the following: 
a) How frequently have you experienced this symptom?  [rarely, sometimes, often, 
always] 
b) How would you rate the intensity/discomfort of this symptom?  [mild, moderate, 
severe] 
c) When did you first experience this symptom during this reporting period?  
[MM/DD/YYYY] 
d) When did you last experience this symptom during this reporting period?  
[MM/DD/YYYY] 
 
